NovoCure Limited (NVCR)
(Delayed Data from NSDQ)
$12.64 USD
+0.41 (3.31%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $12.64 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Price, Consensus and EPS Surprise
NVCR 12.64 +0.41(3.31%)
Will NVCR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVCR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NVCR
Cencora (COR) to Report Q2 Earnings: What's in the Cards?
NovoCure (NVCR) Expected to Beat Earnings Estimates: Should You Buy?
NVCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Medpace (MEDP) Beats Q1 Earnings Estimates
NovoCure (NVCR) Moves to Buy: Rationale Behind the Upgrade
NovoCure (NVCR) Soars 12.0%: Is Further Upside Left in the Stock?
Other News for NVCR
These Are The Biotechs Showing Up At The Biggest Cancer Meeting Of The Year (Oral Presentations)
Results of Novocure’s METIS Phase 3 Clinical Trial for Patients with Brain Metastasis from Non-Small Cell Lung Cancer to be Presented as Late-Breaking Abstract at ASCO 2024
Novocure to present results of METIS phase 3 trial at ASCO 2024
Commit To Buy NovoCure At $7.50, Earn 15.3% Using Options
Buy Rating on NovoCure: Promising METIS Therapy and Strategic Commercial Execution